Clinical and biochemical validation of two endophenotypes of schizophrenia defined by levels of polyunsaturated fatty acids in red blood cells

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 87, Issue 1, 2012, Pages 35-41

  Bentsen, H ^a,b   Solberg, D K ^a   Refsum, H ^a   Bohmer T ^b  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

Author keywords

Endophenotypes; Erythrocytes; Fatty acids; Negative symptoms; Schizophrenia; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; C REACTIVE PROTEIN; CALCIUM; CLOZAPINE; FERRITIN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; POLYUNSATURATED FATTY ACID; QUETIAPINE; TRIACYLGLYCEROL; URIC ACID;

ADULT; AKATHISIA; ARTICLE; BODY MASS; CONTROLLED STUDY; ENDOPHENOTYPE; ERYTHROCYTE; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOKINESIA; INTENTION TO TREAT ANALYSIS; LABORATORY TEST; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR HEMOGLOBIN; MENTAL DISEASE; NEGATIVE SYNDROME; OBESITY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SCORING SYSTEM; SKIN DISEASE; SOMNOLENCE; SPLIT VERSION SYMPTOM SCALE AND FUNCTION SCALE; THROMBOCYTE COUNT; TREMOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BIOLOGICAL MARKERS; CLOZAPINE; DIBENZOTHIAZEPINES; ENDOPHENOTYPES; ERYTHROCYTES; FATTY ACIDS, UNSATURATED; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; LINEAR MODELS; LOGISTIC MODELS; MALE; OBESITY; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84864085703     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2012.05.005     Document Type: Article

References (58)

1. Horrobin D.F, Glen A.I.M, Vaddadi K The membrane hypothesis of schizophrenia. Schizophr. Res. 1994, 13:195-207.
2. Do K.Q, Cabungcal J.H, Frank A, Steullet P, Cuenod M Redox dysregulation, neurodevelopment, and schizophrenia. Curr. Opin. Neurobiol. 2009, 19:220-230.
3. Bentsen H, Solberg D.K, Refsum H, et al. Bimodal distribution of polyunsaturated fatty acids in schizophrenia suggests two endophenotypes of the disorder. Biol. Psychiatry 2011, 70:97-105.
4. Glen A.I, Glen E.M, Horrobin D.F, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases. Schizophr. Res. 1994, 12:53-61.
5. Peet M, Laugharne J, Rangarajan N, Horrobin D, Reynolds G Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients. J. Psychiatr. Res. 1995, 29:227-232.
6. S.R.Kay, Positive and negative syndromes in Schizophrenia. Assessment and Research, Brunner/Mazel, New York, 1991.
7. Bentsen H, Munkvold O.G, Notland T.H, et al. The interrater reliability of the Positive and Negative Syndrome Scale (PANSS). Int. J. Meth. Psychiatr. Res. 1996, 6:227-235.
8. Pedersen G, Hagtvet K.A, Karterud S Generalizability studies of the Global Assessment of Functioning-Split version. Compr. Psychiatry 2007, 48:88-94.
9. Lingjærde O, Ahlfors U.G, Bech P, Dencker S.J, Elgen K The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. 1987, 76:1-100.
10. L.N.W.Daae, G.S.B.Lillesund, P.Urdal, [Medical laboratory investigations at the Oslo hospitals], Oslo Hospitals, Oslo,2000.
11. Arndt S, Turvey C, Andreasen N.C Correlating and predicting psychiatric symptom ratings: Spearman's r versus Kendall's tau correlation. J. Psychiatr. Res. 1999, 33:97-104.
12. Fitzmaurice G.M, Laird N.M, Ware J.H Applied Longitudinal Analysis 2004, John Wiley & Sons, Inc., Hoboken, New Jersey.
13. Bender R, Lange S Adjusting for multiple testing-when and how?. J. Clin. Epidemiol. 2001, 54:343-349.
14. Schulz K.F, Grimes D.A Multiplicity in randomised trials I: endpoints and treatments. Lancet 2005, 365:1591-1595.
15. Streiner D.L, Norman G.R Correction for multiple testing: is there a resolution?. Chest 2011, 140:16-18.
16. Graff-Iversen S, Jenum A.K, Grotvedt L, Bakken B, Selmer R.M, Sogaard A.J [Risk factors for myocardial infarction, stroke and diabetes in Norway]. [Norwegian]. Tidsskr. Nor. Laegeforen. 2007, 127:2537-2541.
17. Yao J.K, Reddy R, McElhinny L.G, van Kammen D.P Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophr. Res. 1998, 32:1-8.
18. Sirota P, Gavrieli R, Wolach B Overproduction of neutrophil radical oxygen species correlates with negative symptoms in schizophrenic patients: parallel studies on neutrophil chemotaxis, superoxide production and bactericidal activity. Psychiatry Res. 2003, 121:123-132.
19. Barshtein G, Ponizovsky A.M, Nechamkin Y, Ritsner M, Yedgar S, Bergelson L.D Aggregability of red blood cells of schizophrenia patients with negative syndrome is selectively enhanced. Schizophr. Bull. 2004, 30:913-922.
20. Cicha I, Suzuki Y, Tateishi N, Maeda N Changes of RBC aggregation in oxygenation-deoxygenation: pH dependency and cell morphology. Am. J. Physiol. Heart Cir. Physiol. 2003, 284:H2335-H2342.
21. Meyer J.M, Koro C.E The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr. Res. 2004, 70:1-17.
22. Meyer J.M, Davis V.G, Goff D.C, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1. Schizophr. Res. 2008, 101:273-286.
23. Sethom M.M, Fares S, Bouaziz N, et al. Polyunsaturated fatty acids deficits are associated with psychotic state and negative symptoms in patients with schizophrenia. Prostaglandins Leukot. Essent. Fatty Acids 2010, 83:131-136.
24. Malla A.K, Norman R.M, Takhar J, et al. Can patients at risk for persistent negative symptoms be identified during their first episode of psychosis?. J. Nerv. Ment. Dis 2004, 192:455-463.
25. Carver J.D, Benford V.J, Han B, Cantor A.B The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 2001, 56:79-85.
26. Yao J, Stanley J.A, Reddy R.D, Keshavan M.S, Pettegrew J.W Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid metabolites. Biol. Psychiatry 2002, 52:823-830.
27. Kitajka K, Sinclair A.J, Weisinger R.S, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gene expression. Proc. Natl. Acad. Sci. USA 2004, 101:10931-10936.
28. Darios F, Davletov B Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. Nature 2006, 440:813-817.
29. Potkin S.G, Alva G, Fleming K, et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. Am. J. Psychiatry 2002, 159:227-237.
30. Berger G.E, Wood S.J, Wellard R.M, et al. Ethyl-eicosapentaenoic acid in first-episode psychosis. A 1H-MRS study, Neuropsychopharmacology 2008, 33:2467-2473.
31. Severance E.G, Dickerson F.B, Halling M, et al. Subunit and whole molecule specificity of the anti-bovine casein immune response in recent onset psychosis and schizophrenia. Schizophr. Res. 2010, 118:240-247.
32. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
33. Motoyama K.R, Curb J.D, Kadowaki T, et al. Association of serum n-6 and n-3 polyunsaturated fatty acids with lipids in 3 populations of middle-aged men. Am. J. Clin. Nutr. 2009, 90:49-55.
34. Nelson G.J, Schmidt P.C, Bartolini G, et al. The effect of dietary arachidonic acid on plasma lipoprotein distributions, apoproteins, blood lipid levels, and tissue fatty acid composition in humans. Lipids 1997, 32:427-433.
35. Lai C.Q, Corella D, Demissie S, et al. Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: The Framingham Heart Study. Circulation 2006, 113:2062-2070.
36. Finnegan Y.E, Minihane A.M, Leigh-Firbank E.C, et al. Plant- and marine-derived n-3 polyunsaturated fatty acids have differential effects on fasting and postprandial blood lipid concentrations and on the susceptibility of LDL to oxidative modification in moderately hyperlipidemic subjects. Am. J. Clin. Nutr 2003, 77:783-795.
37. Mensink R.P, Zock P.L, Kester A.D.M, Katan M.B Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am. J. Clin. Nutr. 2003, 77:1146-1155.
38. Guillou H, Martin P.G, Pineau T Transcriptional regulation of hepatic fatty acid metabolism. Subcell. Biochem 2008, 49:3-47.
39. Chakravarthy M.V, Pan Z, Zhu Y, et al. New hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metabolism 2005, 1:309-322.
40. Vestri H.S, Maianu L, Moellering D.R, Garvey W.T Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 2007, 32:765-772.
41. Ferno J, Vik-Mo A.O, Jassim G, et al. Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver. Psychopharmacology (Berl) 2009, 203:73-84.
42. Vik-Mo A.O, Birkenaes A.B, Ferno J, Jonsdottir H, Andreassen O.A, Steen V.M Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int. J. Neuropsychopharmacol. 2008, 11:679-684.
43. Ryazantseva N.V, Novitskii V.V, Stepovaya E.A, Bulavina Y.V, Fokin V.A Typical changes of reversible erythrocyte aggregation in various pathological processes. Bull. Exp. Biol. Med. 2003, 135:26-28.
44. Toker S, Rogowski O, Melamed S, et al. Association of components of the metabolic syndrome with the appearance of aggregated red blood cells in the peripheral blood. An unfavorable hemorheological finding. Diabetes Metab. Res. Rev 2005, 21:197-202.
45. Hope S, Melle I, Aukrust P, et al. Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disorders 2009, 11:726-734.
46. Stefansson H, Ophoff R.A, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
47. Hatta K, Takahashi T, Nakamura H, et al. Laboratory findings in acute schizophrenia. Relevance to medical management on emergency admission. Gen. Hosp. Psychiatry 1999, 21:220-227.
48. Feelders R.A, Vreugdenhil G, Eggermont A.M, Kuiper-Kramer P.A, van Eijk H.G, Swaak A.J Regulation of iron metabolism in the acute-phase response: interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur. J. Clin. Invest. 1998, 28:520-527.
49. Dickerson F, Stallings C, Origoni A, Boronow J, Yolken R C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr. Res. 2007, 93:261-265.
50. Franch-Arcas G The meaning of hypoalbuminaemia in clinical practice. Clin. Nutr. 2001, 20:265-269.
51. Wong C.T, Tsoi W.F, Saha N Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr. Res. 1996, 22:165-171.
52. Yao J.K, Reddy R, van Kammen D.P Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 2000, 97:137-151.
53. Reddy R, Keshavan M, Yao J.K Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophr. Res. 2003, 62:205-212.
54. Pae C.U, Paik I.H, Lee C, Lee S.J, Kim J.J, Lee C.U Decreased plasma antioxidants in schizophrenia. Neuropsychobiology 2004, 50:54-56.
55. Goldwasser P, Feldman J Association of serum albumin and mortality risk. J. Clin. Epidemiol. 1997, 50:693-703.
56. Simopoulos A.P Evolutionary aspects of the dietary omega-6:omega-3 fatty acid ratio: medical implications. World Rev. Nutr. Dietetics 2009, 100:1-21.
57. Calder P.C The relationship between the fatty acid composition of immune cells and their function. Prostaglandins Leukot. Essent. Fatty Acids 2008, 79:101-108.
58. Buchanan R.W Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33:1013-1022.